Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 47, Issue 4, 2007, Pages 262-272

  Watson, Cathy ^a   Calabretto, Helen ^b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Candidiasis; Chronic disease; Complementary therapies; Recurrent; Thrush

Indexed keywords

ALLERGEN; ALLICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; BORIC ACID; CLOTRIMAZOLE; CRYSTAL VIOLET; ETHINYLESTRADIOL PLUS ETONOGESTREL; FLUCONAZOLE; FLUCYTOSINE; GARLIC EXTRACT; HYDROCORTISONE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; NATURAL PRODUCT; NUVA RING; NYSTATIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; POLYENE; PROBIOTIC AGENT; PYRROLE; SPERMICIDAL AGENT; TEA TREE OIL; THREELAC; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOGHURT;

ABDOMINAL PAIN; ALLERGY; ALTERNATIVE MEDICINE; AMENORRHEA; BLEEDING; BLOATING; BONE DENSITY; BURNING SENSATION; CANDIDA; CANDIDA GLABRATA; CHEMICAL BURN; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DIET; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLATULENCE; GYNECOMASTIA; HEART FAILURE; HEARTBURN; HUMAN; IMMUNOTHERAPY; INFECTION; LACTOBACILLUS ACIDOPHILUS; LIFESTYLE; LIVER DISEASE; LIVER TOXICITY; MENSTRUAL IRREGULARITY; NAUSEA; PATIENT COMPLIANCE; PATIENT INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; RELAPSE; REMISSION; REVIEW; SEXUAL TRANSMISSION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN ALLERGY; SKIN IRRITATION; SOMNOLENCE; SPOTTING; SYMPTOM; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA DISEASE; WEIGHT GAIN;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS, VULVOVAGINAL; CHRONIC DISEASE; COMPLEMENTARY THERAPIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENTIAN VIOLET; HUMANS; LACTOBACILLUS; MENSTRUAL CYCLE; PROBIOTICS; RECURRENCE;

EID: 34447507898     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2007.00736.x     Document Type: Review

References (73)

1. Reef SE, Levine WC, Mcneil MM et.al. Treatment options for vulvovaginal candidiasis. Clin Infect Dis 1995; 20 (Suppl. 1): S80-S90.
2. Calderon-Marquez JJ. Itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner. Rev Infect Dis 1987; 9: S143-S145.
3. Nyirjesy P, Weitz M, Grody MH, Lorber B. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms. Obstet Gynecol 1997; 90: 50-53.
4. Adis Data Information BV. Maintenance suppressive azole antifungal regimens are a major advance in controlling recurrent vulvovaginal candidiasis. Drugs Ther Perspect 2004; 20: 7-11.
5. Saporiti AM, Gomez D, Levalle S et.al. Vaginal candidiasis: Etiology and sensitivity profile to antifungal agents in clinical use. Rev Argent Microbiol 2001; 33: 217-222.
6. Nyirjesy P. Chronic vulvovaginal candidiasis. Am Fam Physician 2001; 63: 697-702.
7. Sheary B, Dayan L. Clinical practice. Recurrent vulvovaginal candidiasis. Aust Fam Physician 2005; 34: 147-150.
8. Geller ML, Nelson AL. Bacterial vaginosis and vulvovaginal candidiasis. Women's Health Prim Pract 2003; 6: 537-548.
9. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000; 61: 3306-3312, 3317.
10. Therapeutic Goods Administration. Therapeutic Guidelines Ltd. Antibiotic, Version 13. eTG complete. Melbourne, Vic.: Therapeutic Guidelines Limited, 2006 January. [Accessed 18 October 2006.]Available from http://www.tg.com.au/ip/complete/.
11. Prodigy Knowledge. The Management of Genital Thrush (Vulvo-Vaginal Candidiasis) in Women. Candida-Female Genital. 2005. Crown Copyright, Department of Health 1998-2004. [Accessed 2 November 2006.]Available from http://www.prodigy.nhs.uk/candida_female_genital.
12. White DJ, Vanthuyne A, Wood PM, Ayres JG. Zafirlukast for severe recurrent vulvovaginal candidiasis: An open label pilot study. Sex Transm Infect 2004; 80: 219-222.
13. Sobel JD, Faro S, Force RW et.al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203-211.
14. Clinical Effectiveness Group (CEG). National Guideline on the Management of Vulvovaginal Candidiasis. 2002. London, UK: ECG, University of London. [Accessed 10 October 2006.]Available from http://www.bashh.org/ guidelines/2002/candida_0601.pdf.
15. Mardh PA, Novikova N, Stukalova E. Colonisation of extragenital sites by candida in women with recurrent vulvovaginal candidosis. BJOG 2003; 110: 934-937.
16. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992; 14 (Suppl. 1): S148-S153.
17. Fidel PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 9: 335-348.
18. Fidel PL Jr, Barousse M, Espinosa T et.al. Infect Immun 2004; 72: 2939-2946.
19. Fong IW. The rectal carriage of yeast in patients with vaginal candidiasis. Clin Invest Med 1994; 17: 426-431.
20. O'Conner MI, Sobel JD. Epidemiology of recurrent vulvovaginal candidiasis: Identification and strain differentiation of Candida albicans. J Infect Dis 1986; 154: 358-363.
21. Spinillo A, Carratta L, Pizzoli G et.al. Recurrent vaginal candidiasis. Results of a cohort study of sexual transmission and intestinal reservoir. J Reprod Med 1992; 37: 343-347.
22. Lacour M, Zunder T, Huber R Sander A, Daschner F, Frank U. The pathogenetic significance of intestinal Candida colonization: A systematic review from an interdisciplinary and environmental medical point of view. Int J Hyg Environ Health 2002; 205: 257-268.
23. Fong IW. The value of treating the sexual partners of women with recurrent vulvovaginal candidiasis with ketoconazole. Genitourin Med 1992; 68: 174-176.
24. Bisschop MP, Merkus JM, Scheygrond H, Van Cutsem J. Co-treatment of the male partner in vaginal candidosis: A double-blind randomized control study. Br J Obstet Gynaecol 1986; 93: 79-81.
25. Reed BD, Zazove P, Pierson CL, Gorenflo DW, Horrocks J. Candida transmission and sexual behaviors as risks for a repeat episode of candida vulvovaginitis. J Womens Health (Larchmt) 2003; 12: 979-989.
26. White DJ, Drake SM. Management of genital candidiasis. BMJ 1995; 311: 629.
27. Tasic S, Tasic N, Tasic A, Mitrovic A. Recurrent genital candidosis of women; consequence of reinfection of relapse. Med Biol 2002; 9: 217-222.
28. Dennerstein GJ. The treatment of candida vaginitis and vulvitis. Aust Prescr 2001; 24: 62-64.
29. Moraes PS. Recurrent vaginal candidiasis and allergic rhinitis: A common association. Ann Allergy Asthma Immunol 1998; 81: 165-169.
30. Neves NA, Carvalho LP, De Oliveira M et.al. Association between atopy and recurrent vaginal candidiasis. Clin Exp Immunol 2005; 142: 167-171.
31. Neves NA, Carvalho LP, Lucas P, Lopes AC, Cruz A, Carvalho E. Successful treatment of refractory recurrent vaginal candidiasis with cetrizine plus fluconazole. J Low Genit Tract Dis 2005; 9: 167-170.
32. Macneill C, Carey JC. Recurrent vulvovaginal candidiasis. Curr Women Health Rep 2001; 1: 31-35.
33. El-Din S, Reynolds M, Ashbee H, Barton R Evans E. An investigation into the pathogenesis of vulvo-vaginal candidosis. Sex Transm Infect 2001; 77: 179-183.
34. Spence D. Candidiasis (vulvovaginal). In: Godlee F, ed. Clinical Evidence [online book]. London: BMJ Publishing Group Pty Ltd, 2005.
35. Sobel JD, Schmitt C, Meriwether C. Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstet Gynecol 1989; 73: 330-334.
36. Sobel JD, Schmitt C, Stein G, Mummaw N, Christensen S, Meriwether C. Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole. J Reprod Med 1994; 39: 517-520.
37. Sobel JD, Wiesenfeld HC, Martens M et.al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Eng J Med 2004; 351: 876-883.
38. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2006, Issue 3. Art. No.:CD002845. DOI: 10.1002/14651.
39. Eschenbach DA, Thwin SS, Patton DL et.al. Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin Infect Dis 2000; 30: 901-907.
40. Kozel TR, Fidel PL, Cutright J, Stelle C. Effects of reproductive hormones on experimental vaginal candidiasis. Infect Immun 2000; 68: 651-657.
41. Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Esenbach DA, Holmes K. Vulvovaginal candidiasis: Clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998; 92: 757-765.
42. Lopez-Olmos J, Lerma E. Treatment of recurring vulvo-vaginal candidiasis: A comparative prospective study during six months of three anti-myotic preparations of a single dose. Clin Invest Ginecol Obstet 2000; 27: 366-375.
43. Roth AC, Milsom I, Forssman L, Wahlen P. Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourin Med 1990; 66: 357-360.
44. Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. Drugs 2003; 63: 1059-1066.
45. Guaschino S, De Seta F, Sartore A et.al. Efficacy of maintenance therapy with boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2001; 184: 598-602.
46. NHS. An update on vulvovaginal candidiasis (thrush). MeReC Bulletin 2004; 14; MeReC Publications. NICS.
47. Coulter ID, Willis EM. The rise and rise of complementary and alternative medicine: A sociological perspective. MJA 2004; 180: 587-589.
48. Magliani W, Conti S, Salati A et.al. New strategies for treatment of Candida vaginal infections. Rev Iberoam Micol 2002; 19: 144-148.
49. Miller L, Patton D, Meier A et.al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol Surv 2000; 96: 431-439.
50. Toppozada M, Onsy F, Fares E, Amir S, Shaala S. The protective influence of progestogen only contraception against vaginal moniliasis. Contraception 1979; 20: 99-103.
51. Dennerstein G. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med 1986; 31: 801-803.
52. Kaunitz A. Injectable depot medroxyprogesterone acetate contraception: An update for U.S. clinicians. Int J Fertil Womens Med 1998; 43: 73-83.
53. Clark MK, Sowers M, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004; 82: 1580-1586.
54. Gbolade B, Ellis S, Murby B, Randal S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 1998; 105: 790-794.
55. Metts J, Famula T, Trenev N, Clemens R. Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. J Appl Res 2003; 3: 340-348.
56. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT. Ingestion of yoghurt containing acidophilus as prophylaxix for candidal vaginitis. Ann Intern Med 1992; 116: 353-357.
57. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: A review. J Antimicrob Chemother 2006; 58: 266-272.
58. Moore GS, Atkins RD. The fungicidal and fungistatic properties of an aqueous garlic extract on the medically important yeast-like fungi. Mycologia 1977; 69: 341-348.
59. Van Kessel K, Assefi N, Marrazzo J, Eckert L. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic review. Obstet Gynecol Surv 2003; 58: 351-358.
60. Thompson Healthcare Inc. DRUGDEX® Drug Point Gentian Violet. MICROMEDIX. 1974-2006. Micromedex® Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Micromedex. Updated periodically. [Accessed 23 October 2006.]Available from Clinician's Health Channel.
61. Diehl KB. Topical antifungal agents: An update. Am Fam Physician 1996; 54: 1687-1693.
62. Littlefield NA, Blackwell BN, Hewitt CC, Gaylor DW. Chronic toxicity and carcinogenicity studies of Gentian violet in mice. Fundamental Appl Toxicol 1985; 5: 902-912.
63. Jovanovic R Congema R Nguyen H. Antifungal agents vs Boric Acid for treating chronic myotic vulvovaginitis. J Reprod Med 1991; 36: 593-597.
64. Haefner HK. Current evaluation and management of vulvovaginitis. Clin Obstet Gynecol 1999; 42: 184-195.
65. White DJ, Johnson EM, Warnock DW. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993; 69: 112-114.
66. Glenville M. Thrush, Vaginal. The Natural Health Website for Women. 2001-2006. UK. [Accessed 12 September 2006.]Available from http://www.marilynglenville.com/.
67. Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts. J Antimicrob Chemother 2003; 51: 1223-1229.
68. Hammer KA, Carson CF, Riley TV. In-vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree oil products, against Candida spp. J Antimicrob Chemother 1998; 42: 591-595.
69. Ernst E, Huntley A. Tea tree oil: A systematic review of randomised clinical trials. Forsch Komplementarmed, Klass Naturheilked (Research in Complementary Medicine) 2000; 7: 17-20.
70. Martino JL, Vermund SH. Vaginal douching: Evidence for risks or benefits to women's health. Epidemiol Rev 2002; 24: 109-124.
71. Patel DA, Gillespie B, Sobel JD et.al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study. Am J Obstet Gynecol 2004; 190: 644-653.
72. Mardh PA, Novikova N, Stukalova E. Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candidosis. BJOG 2003; 110: 934-937.
73. Friedrich EG Jr, Phillips LE. Microwave sterilization of Candida on underwear fabric. J Reprod Med 1988; 33: 421-422.